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Abstract
Introduction. Animal models designed to mimic certain features of Alzheimer’s disease (AD) can help us to in-
crease our understanding of the underlying mechanisms of disease. Previous studies have revealed that long-term 
D-galactose injection combined with ovariectomy results in pathophysiologic alterations associated with AD. Thus, 
the aim of the present study was to investigate the effects of rosmarinic acid (RA) administration on pathological 
changes associated with ovariectomy and D-galactose injection, which serve as a two-insult model for AD. 
Material and methods. One hundred female Wistar rats were divided into five equal groups: control (C), Sham 
(Sh), rosmarinic acid treated (R), ovariectomized rats treated with D-galactose (OD), ovariectomized rats 
treated with D-galactose and rosmarinic acid (ODR) groups. D-galactose (80 mg/kg/day) was administered by 
i.p. injection and RA (50 mg/kg/day) was given via gavage for 60 days. Open field and Y-maze tests were used 
to assess locomotor activity and short-term spatial memory, respectively. Biochemical and histopathological 
analyses of the brain tissue were performed. 
Results. Open field testing showed that the locomotor activity and exploratory behavior of rats were prominent-
ly impaired in the OD group as compared to the other studied groups. Similarly, Y-maze test results revealed 
a decrease of short-term spatial memory in the OD rats. A concomitant treatment with RA significantly restored 
altered locomotor activity and cognitive functions in the ODR group. Lipid peroxidation levels, cyclooxygen-
ase-2 expression and prostaglandin E2 levels in the brain tissue were higher in the OD group and RA treatment 
inhibited these changes. AD-like histopathological alterations and amyloid b peptide (Ab) depositions were 
observed in the OD group. Normal cell structure and lower Ab depositions were observed in the ODR group 
compared with the OD group. 
Conclusions. RA could have the potential to prevent some psychological and biochemical alterations of brain 
tissue found in a rat model of AD probably by attenuating lipid peroxidation and inflammatory response. (Folia 
Histochemica et Cytobiologica 2015, Vol. 53, No. 4, 283–293)
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Introduction
The deleterious consequences and pathophysiological 
role of increased reactive oxygen species (ROS) pro-
duction are well known in Alzheimer’s disease (AD) [1]. 
The early involvement of oxidative stress in AD is 
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demonstrated by oxidative modifications of lipids [2, 3] 
and proteins [4, 5] in brains from AD patients, and 
also in animal models of AD. Additionally, overex-
pression of cyclooxygenase-2 (COX-2) and elevated 
levels of prostaglandin E2 (PGE2) [6, 7] have been 
observed in the AD. Since PGE2, a principal proin-
flammatory product of COX-2 enzymatic activity, is 
a potent inducer of inflammation [8, 9], it could be 
expected that attenuating COX-2 and PGE2 signaling 
and free radical damage may represent good thera-
peutic targets against progresssion of AD.
In a rat model of AD molecular alterations can be 
induced by long-term ovarian hormone deprivation 
combined with D-galactose (D-gal) treatment [10, 11]. 
It is well known that estrogen deprivation [12, 13] 
and oxidative stress [14, 15] have been implicated 
as important risk factors in the pathogenesis of AD. 
Estrogen deficiency after menopause has been shown 
to contribute to AD development and considering the 
reported neuroprotective effects of estrogens [16], es-
trogen replacement therapy (ERT) has been suggested 
to be useful for preventing the onset of this disease. 
However, considering the well-defined side effect of 
ERT [17, 18], the use of estrogen as a treatment for AD 
is limited. Hence, there is a need to develop alternative 
AD therapeutic agents with fewer side effects.
Members of the Salvia species, such as Salvia offici­
nalis and Salvia lavandulaefolia, have a long history of 
usage as traditional herbal medicine in many cultures. 
Salvia extract is generally known for its multiple 
biological activities including anticholinergic, anti-in-
flammatory and antioxidant properties potentially 
relevant to brain function [19, 20]. In previous clinical 
studies, it was shown that Salvia extracts improved 
cognitive performance and enhanced positive mood 
in young healthy volunteers [21–23]. In addition, 
a Salvia extract improved memory and attention in 
healthy older subjects by its cholinesterase inhibiting 
properties by inhibiting cholinesterase activities [24]. 
Beside healthy individuals, a randomized double-blind 
clinical study showed that an ethanolic extract from 
Salvia officinalis which contains rosmarinic acid (RA) 
was effective in the management of mild to moderate 
AD [25, 26]. Rosmarinic acid is a naturally occurring 
phenolic compound that is known for its antioxidant, 
anti-cholinergic and anti-inflammatory activities [27– 
–30]. So, the aim of the present study was to investigate 
possible protective effect of RA on symptoms seen in 
the AD rat model by behavioral, neurochemical and 
histopathological analyses. 
Material and methods
Animals. The study protocol was approved by Akdeniz Uni-
versity Animal Care and Use Committee. A hundred healthy 
female albino Wistar rats, aged five months, weighing 300 to 
350 g were used. Animals were housed in stainless steel cages 
in groups of 4 rats per cage at standard conditions (24 ± 2°C 
and 50 ± 5% humidity) with 12 h light-dark cycle and given 
food and water ad libitum. The experiments were performed 
between 9:00 and 17:00. Rats were randomly divided into five 
groups (n = 20 per group): Group 1: control (C); Group 2: 
rats were sham operated and treated with saline (SH); Group 3: 
rats were treated with rosmarinic acid (R); Group 4: 
rats were ovariectomized and treated with D-gal (OD; AD 
model); Group 5: rats were ovariectomized and treated 
concomitantly with D-gal and rosmarinic acid (ODR). D-ga-
lactose (Sigma-Aldrich, St. Louis, MO, USA; 80 mg/kg/day, 
80 mg of D-gal dissolved in 0.9% saline solution, to a total 
volume of 1 mL) was administered by i.p. injection and RA 
(Carbosynth, San Diego, CA, USA; 50 mg/kg/day, 50 mg of 
RA dissolved in 0.9% saline solution, to a total volume of 
1 mL) was given via gavage for 60 days. Physiologic saline 
was administered by i.p. injection and gavage to the SH 
group for the same period of time. 
Tissue preparation. After behavioral tests, rats were deeply 
anesthetized with urethane and brains of rats were perfused 
transcardially with heparinized saline, removed immediately 
and stored at −80°C for biochemical analysis. For immunohis-
tochemical studies, after transcardial perfusion with cold 0.9% 
saline followed by 4% paraformaldehyde (for immunohisto-
chemistry, n = 5) or with 0.5% glutaraldehyde (for electron 
microscopy, n = 3) in phosphate-buffered saline (PBS, 0.01 M, 
pH 7.4), the brains were removed and post-fixed overnight 
or 3 h at 4°C in the same solutions, respectively. 
Immunohistochemistry. For anti-Ab antibody immunohis-
tochemistry, sections were deparaffinized and blocked for 
endogenous peroxidase activity and nonspecific binding 
(BioGenex, San Ramon, CA, USA). Rabbit anti-Ab 40/42 
antibody (1:200; Cell Signaling, Saint Louis, MO, USA) was 
applied for 1 h at room temperature. For negative control the 
primary antibody was replaced by normal rabbit IgG serum 
(Vector Laboratories, Burlingame, CA, USA) at the same 
concentration. After several washes, sections were incubated 
with biotinylated goat anti-rabbit IgG secondary antibody 
(1:400 dilution, Vector Lab.) followed by LSAB streptavi-
din-peroxidase complex (Dako, Carpinteria, CA, USA) 
incubation and were rinsed with PBS. Antibody complex was 
visualized by incubation with diaminobenzidine chromogen 
(BioGenex). Sections were counterstained with Mayer’s 
hematoxylin (Dako), dehydrated, mounted and examined on 
a Zeiss-Axioplan, microscope (Zeiss, Oberkochen, Germa-
ny). Ab levels were quantified using Image J (1.48v) software 
(NIH, USA), which confers semi-quantitatively analysis of 
immunohistochemical staining. 
Transmission electron microscopy. Samples of hippocampus 
were dissected from brain and fixed with 4% glutaraldehyde, 
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prepared in 0.1 M Sorensens’s phosphate buffer solution 
(pH 7.4). Then, samples were postfixed with 1% osmium 
tetraoxide in the same buffered solution. After dehydration 
through a graded series of ethanol, they were embedded in 
epoxy resin (Araldite CY212, Agar Scientific Ltd, Stansted, 
UK). Semi-thin (1 mm) and ultrathin (40–60 nm) sections 
were cut with an ultramicrotome (Leica ultracut, UCT, Leica 
MZ6, England). Semi-thin sections (1 µm) were stained with 
toluidine blue and were examined with a light microscope 
(Olympus CX41, Tokyo, Japan) for orientation. Afterwards, 
ultrathin sections (40–60 nm) were contrasted with uranyl 
acetate and Reynold’s lead nitrate and were examined with 
a transmission electron microscope (LEO 906E model, 
Zeiss) [31]. Ultrastructural analysis was performed on the 
CA1 granular layer of the hippocampus to mainly focus on 
the morphologic changes of the nucleus, cytoplasmic orga-
nelles. For analysis of morphologic changes of organelles in 
the CA1, neurons in this layer were randomly selected and 
examined at ×6000 magnification. 
Determination of thiobarbituric acid reactive substances 
(TBARS). Levels of TBARS were measured by a fluorimetric 
method described by Wasowicz et al. [32], using 1,1,3,3-tetra-
ethoxypropane as a standard. Brain tissues (n = 10 per 
group) were weighed and homogenized (Bio-Gen Pro-200) 
in an ice cold 50 mM potassium phosphate buffer at pH 7.0. 
Homogenates were centrifuged (10.000 g, 15 min, 4°C) 
(3-18K centrifuge, Sigma-Aldrich) and supernatants were 
used for lipid peroxidation analysis. All measurements were 
performed in duplicate and assay was repeated three times. 
The results are given as nmol/g protein.
Western Blot analysis of 4-hydroxy-2-nonenal (4-HNE) and 
COX-2 proteins. Protein concentrations in all samples were 
measured spectrophotometrically by a protein assay reagent 
kit (Pierce, Rockford, IL, USA) via a modified Bradford 
method. Bovine serum albumin was used as standard. West-
ern blot analysis was performed as previously described [33]. 
A rabbit polyclonal COX-2 antibody (1:200 dilution; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 
a rabbit polyclonal 4-HNE antibody (1:1000 dilution) were 
used for Western blot (WB) analysis. Horseradish perox-
idase-conjugated goat anti-rabbit IgG (1:10000 dilution; 
Zymed Laboratories, San Francisco, CA, USA) was used 
as a secondary antibody and immunoreactive proteins were 
visualized on high performance chemiluminescence film via 
ECL (enhanced chemiluminescence) reagent (Amersham 
Pharmacia Biotech, Buckinghamshire, UK). Western blot-
ting was performed two times. Densitometric analysis of 
immunoblots was performed using NIH image 1.61 software 
for windows (Scion Corporation, Frederick, MD, USA).
Measurement of PGE2 content in hippocampus. For deter-
mination of PGE2, isolated hippocampus tissues (n = 10 per 
group) were placed in Tris-HCl buffer (pH 7.5) with 0.02 M 
EDTA and 5 mg/mL indomethacin. PGE2 collection and 
purification was done according to a modified protocol 
supplied with the PGE2 EIA system (Cayman Chemical 
Company, Ann Arbor, MI, USA). The quantity of PGE2 
was measured by enzyme immunoassay (EIA) according to 
the protocol provided with the EIA kit (Cayman). The assay 
was performed in duplicate and repeated twice.
Locomotor activity test. At the end of the 60 days experi-
mental period, locomotion and exploratory behavior of rats 
were observed in a brightly illuminated square-shaped arena 
(50 cm × 50 cm). The animal was placed in the center and 
allowed to explore the open field for 5 min. The locomotor 
activity (path-length, resting time) was assessed using an au-
tomated tracking system (MAY ACT508, animal locomotor 
activity meter, Commat Ltd., Ankara, Turkey). After each 
test the arena was cleaned with 70% ethanol.
Short-term memory assessment by Y-maze test. After a 2-day 
rest period following locomotor activity test, short-term 
spatial memory was assessed using the Y-maze [34], which 
consisted of three arms made of black Plexiglas. The stem 
arm and the two arms forming the Y were 42 and 37 cm 
long, respectively, and diverged at a 45° angle from the 
stem arm. The three arms were randomly designated: first 
arm — start arm, in which the rat started to explore (always 
open); second arm — novel arm, which was blocked at the 
1st trial, but open at the 2nd trial; third arm — the other arm 
(always open). In the first phase of the experiment the rat 
was placed at the end of the start arm. During training, 
novel arm was blocked and each rat was allowed to explore 
the start and other arms for 10 min. After a 2 hour interval, 
the rat was replaced in the Y-maze for 5 min and all arms 
were accessible. Rats were interpreted to have intact spatial 
memory if they showed a preference for the novel arm since 
rats have an innate tendency to explore novelty. Behavior 
was recorded on video and the number of times each arm 
was visited and the time spent in each arm was analyzed using 
video tracking (Ethovision XT, Noldus, The Netherlands).
Statistical analysis. The statistical analyses of the obtained 
data were performed by SPSS (version 18.0) software for win-
dows. While results of Western blot were expressed as means 
± standard deviation, other results were expressed as means 
± standard errors. TBARS and locomotor activity values were 
analyzed via one-way analysis of variance (ANOVA) and all 
pairwise multiple comparisons were performed by Tukey’s 
test. The differences in other parameters were analyzed 
via Kruskal-Wallis one-way analysis of variance on ranks, 
and all pairwise multiple comparisons were performed by 
Mann-Whitney U. Additionally, statistical analysis within each 
group for Y-maze data was performed by Wilcoxon paired 
t-test. P values less than 0.05 were considered significant. 
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Results
Immunohistochemistry of amyloid beta expression
There was a very little intraneuronal Ab immuno-
labeling localized in hippocampal areas of C and R 
groups (Figure 1A: C, R). On the other hand, intense 
Ab immunoreactivity was clearly observed in the 
cytoplasm of hippocampal neurons in the OD group 
(Figure 1A: OD). Moreover, there was a moderate 
Ab immunolabeling detected in the hippocampus of 
ODR group (Figure 1A: ODR). Ab immunostaining 
in the ODR group was not as intense as in the OD 
group. Quantitative analysis of Ab stained sections 
revealed higher immunoreactivity in the OD group 
versus the other groups and percentage of stained 
area decreased in the ODR group versus the OD 
group (Figure 1B).
Ultrastructural analysis
The electron microscopic analysis of the brains of 
control (C) rats revealed that the morphology of 
pyramidal neuron’s nucleus (N) and perikaryon (P) 
was normal (Figure 2A). Additionally, cytoplasm and 
structure of organelles seemed also normal with main-
tained mitochondrial membranes structure in this 
group (Figure 2A). In the R group, normal cytoplasm, 
organelle structure together with regular mitochon-
drial (black arrows) and normal Golgi morphology 
(star) were viewed (Figure 2B). In ultrastructural 
analysis of OD group, typical pathological changes 
associated with neurodegeneration were detected in 
CA1 area of hippocampus. In this group, cytoplas-
molysis (stars), edematous endoplasmic reticulum, 
severe crista deformations and mitochondrial swelling 
(black arrows) were observed in perikaryon. Besides 
these changes, wide spread membrane deformation 
(white arrows) and edema in nucleus (N) were also 
detected (Figure 2C). In the ODR group maintained 
mitochondrial membrane structure (arrowheads) 
drew attention in cytoplasm and neuropil of CA1 
pyramidal cell. Nucleus (N) membrane integrity was 
not impaired and normal perinuclear space (white 
arrows) was found (Figure 2D). As seen in Figure 2D, 
axons of hippocampal CA1 pyramidal cell showed 
normal structure and did not contain electron dense 
deposits (black arrows).
Tissue lipid peroxidation
Brain TBARS levels in OD group were significantly 
higher than those detected in other groups. Rosmari-
nic acid significantly decreased TBARS levels in the 
ODR group compared with the OD group. TBARS 
levels were significantly increased in the SH group 
versus C group. Rosmarinic acid treatment alone had 
no impact on lipid peroxidation in the R group with 
measured TBARS levels (Table 1). 
Levels of 4-HNE and COX-2 proteins as measured 
by Western blotting
4-hydroxy-2-nonenal (Figure 3A, B) and COX-2 
(Figure 3C, D) western blots and densitometric analy-
sis of hippocampal tissues from all groups are shown in 
Figure 3. COX-2 protein levels and 4-HNE levels were 
increased in the OD group compared with the others. 
Decreased COX-2 levels were observed in the ODR 
group, compared with the OD group. A decrease in 
4-HNE levels was detected in the hippocampus of the 
OD group treated with RA. Protein staining of brain 
homogenates applied for WB analysis shows equal 
protein loading in each lane (Figure 3E). 
Hippocampal PGE2 content
As seen in Figure 4, PGE2 levels were significantly 
higher in the OD group compared with all other 
groups including ODR. Rosmarinic acid decreased 
PGE2 levels in the ODR group compared with the 
OD group. However, PGE2 levels were significantly 
(p < 0.05) increased in ODR group compared with 
C, SH, and R. 
Locomotor activity test
There was a significant decrease in the distance moved 
by the OD group (p < 0.001) compared to other 
groups. SH and ODR groups showed no significant 
change compared to the C group (Table 2). Distance 
moved by the rats of the R group was significantly 
higher than by rats of other groups. 
A significant decrease in the time of resting was 
seen in the R group (p < 0.001) compared with the 
other groups (Table 2). The OD group showed signi-
ficantly higher resting time when compared with other 
groups, ODR and SH groups showed no significant 
change compared to the C group.
Short memory test (Y-maze test)
The time spent (Figure 5A) and the number of visits 
(Figure 5B) to the novel arm compared with the fa-
miliar “other” arm were significantly lower in the OD 
group versus the other groups. In all groups except 
OD, the time spent in the novel arm was significantly 
higher than those in the other arm. The number of 
visits to the novel arm versus the “other” arm were sig-
nificantly higher in all groups except OD. Rosmarinic 
acid increased the time spent and the number of visits 
in the novel arm versus the “other” arm in the ODR 
group with respect to the OD group. There were no 
significant differences between groups for total arm 
entries, indicating that the deficit observed did not 
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Figure 1. Immunohistochemical staining of amyloid b protein in all experimental groups. A. Representative images of amy-
loid b (Ab) peptide localization in the hippocampus. Middle and right panels show CA1 region. The magnifications are 
×2.5, ×20 and ×40 in left, middle and right panel, respectively; B. Quantitative analysis of Ab staining levels were com-
pared in all groups, using ImageJ software. Results are mean ± SEM, n = 5 in each group. *p < 0.05; difference of ODR 
group versus the other groups, **p < 0.05; difference of OD group versus the other groups. Abbreviations: C — control; 
R — rosmarinic acid (RA) treated; OD — ovariectomized rats treated with D-galactose (D-gal); ODR — ovariectomized 
rats treated with D-gal and RA
A
B
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arise as a consequence of reduced activity in the ODR 
group (data not shown).
Discussion
It is known that estrogen has neurotropic and pro-
tective effects in the brain. In agreement with the 
knowledge that AD is more common in women [35], 
recent studies showed that decreased estrogen level 
is a risk factor for AD and estrogen deficiency has 
been implicated in AD etiology [36, 37]. Beside 
hormonal changes, increased oxidative stress with 
aging is another important risk factor for developing 
AD. The long-term injection of D-gal contributes to 
the oxidative modifications in cerebral tissue, and 
further leads to lipofuscin deposition, slight neuronal 
damage and memory decay which are all prominent 
and early changes in aging [38]. A previous study has 
demonstrated that these two factors have synergistic 
effects on accelerating the progression of AD and 
long-term administration of D-gal (80 mg/kg/day) into 
Figure 2. Representative ultrastructural images of CA1 of hippocampal tissue sections from each experimental group. 
A. The neuron nucleus (N) and the perikaryon structure (P) of the control group. Scale: 1 µm; B. Mitochondrias (black ar-
rows) and Golgi (star), membrane structure of the R group. Scale: 1 µm; C. Nucleus membrane (white arrows), mitochon-
drias (black arrows) and cytoplasmolysis (stars) of the OD group. Scale: 1 µm; D. Nucleus (N), perinuclear space (white 
arrows), mitochondrial membrane (arrowheads) and axons (black arrows) of the ODR group. Scale: 2 µm. n = 3 in each 
group. Abbreviations as in the description of Figure 1
A B
C D
Table 1. Tissue lipid peroxidation expressed by the levels of 
TBARS
Group nmol/g protein
C 0.17 ± 0.07
SH 0.28 ± 0.11*
R 0.17 ± 0.08
OD 0.40 ± 0.13**
ODR 0.20 ± 0.07***
The content of thiobarbituric acid reactive substances (TBARS) was 
measured as described in Material and methods. The results are pre-
sented as mean ± SEM, n = 10 for each group. *Significantly different 
versus the C, R and OD groups, p < 0.05; **Significantly different 
versus the other groups, p < 0.05; ***p < 0.05; significant difference 
between the ODR group versus the OD group
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ovariectomized rats may serve as an AD rodent model 
which can mimic the pathological, neurochemical and 
behavioral alterations observed in AD [10]. Amyloid b 
peptide deposition was examined in the hippocampus 
to confirm that the animal model can mimic the neu-
ropathological manifestations observed in the disease. 
Our findings support previously reported observations 
of Ab immunoreactive neurons which were detected 
in the hippocampus of all ovariectomized rats treated 
with D-gal [10]. Also, in line with the previous study of 
Zhao et al. [39], we detected marked increased in lipid 
peroxidation levels in the OD rats. Our results and 
previously reported findings suggest that endogenous 
Ab peptides aggregate to form amyloid plaques in the 
presence of oxidative and neurodegenerative milieu 
created by D-gal treatment and estrogen deprivation. 
Consistent with the Ab deposition, ultrastructural 
analysis displayed some pathological alterations 
Table 2. Locomotor activity test
Group Distance moved [cm] Resting (%)
C 531.9 ± 61.03 51.5 ± 2.67
SH 556.8 ± 97.8 53.1 ± 6.0
R 825.1 ± 96.08* 39.9 ± 7.51*
OD 198.4 ± 25.9** 72 ± 10.6**
ODR 538.2 ± 96.2 53 ± 5.83
The locomotor activity test was performed as described in Material 
and methods. The results are presented as mean ± SEM, n = 20 for 
each group. *Statistically different versus the other groups, p < 0.001; 
**Statistically different versus the other groups, p < 0.001
Figure 3. Western blotting (WB) analysis. A. WB of 4-HNE proteins; B. Densitometric analysis of 4-HNE proteins;  
C. WB of COX-2 protein; D. Densitometric analysis of COX-2 protein; E. SDS-PAGE analysis of hippocampal homoge-
nates. Brain proteins were separated by SDS-PAGE and visualized by Coomassie blue staining. Results are presented as 
mean of two experiments. Error bars represent the standard deviation of duplicate experiments. n = 1–3 per experiment. 
Abbreviations as in the description of Figure 1
C
D
Figure 4. PGE2 levels in the hippocampus of control and 
experimental rats. The results are presented as mean ± 
SEM, n = 10. *Significant difference between the ODR 
and other groups, p < 0.05; **Significant difference be-
tween the OD and other groups, p < 0.05. Abbreviations  
as in the description of Figure 1
B
E
A
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such as edematous endoplasmic reticulum, severe 
mitochondrial deformations, nucleus membrane 
deformation and edema in OD group. These changes 
were in line with the earlier report revealing degen-
erations in nucleus and organelle structures in D-gal 
administered ovariectomized rats [10]. These data 
are in line with the previous reports which indicate 
that decreased estrogen levels after menopause and 
increased oxidative stress are risk factors for devel-
opment and progression of the disease.
Although a large amount of evidence indicates that 
estrogen plays a neuroprotective role in AD [13, 40], 
ERT is a controversial issue and has been linked to 
increase the risk of certain cancers, like breast and 
uterine cancer [17, 18]. Therefore, RA, which is 
a safe compound, was used in our study as therapeutic 
agent to attenuate the changes associated with AD. 
The therapeutic efficacy of RA has been tested in both 
in vitro and in vivo models of AD. Previous studies 
have been tested the effect of RA on Ab aggregation 
in both in vitro and transgenic mice model of AD 
[41, 42]. It has been reported that RA prevents Ab 
oligomerization under in vitro conditions and that RA 
prevents Ab-induced alterations of neuronal plasticity 
in the CA1 region of mouse hippocampus slices [41]. 
Oral administration of RA decreased the Ab burden 
in the AD model transgenic mice by inhibiting the Ab 
aggregation pathway from Ab monomers to A11-pos-
itive oligomers and from A11-positive oligomers to 
Ab deposition [42]. Although our study supports 
the reported findings above, our experiments were 
performed on a different AD rodent model which 
can completely mimic the neuropathological and 
behavioral alterations in AD by affecting several 
molecular changes associated with deprivation of 
endogenous estrogen and oxidative stress [10, 11]. 
In addition to reduce Ab accumulation, RA reversed 
mitochondrial swelling and crista deformations. Also, 
nucleus membrane integrity was maintained and nor-
mal perinuclear space was vied in the treatment group. 
In a previous study, lipid peroxidation was detected 
before Ab accumulation in 7 months AD transgenic 
mice [43]. In the current study, increase in brain 
TBARS and hippocampus 4-HNE levels in the OD 
group supports previous findings [44, 45] that show the 
importance of lipid peroxidation in the development 
of AD. In support of previous cell culture study [46], 
RA also decreased lipid peroxidation in our study. 
In addition, RA treatment attenuated 4-HNE level 
in the ODR rats. These findings suggest that RA 
could be used against Ab induced oxidative damage 
as a neuroprotective agent and also RA may prevent 
Ab accumulation by decreasing lipid peroxidation. In 
addition, a significant increment in brain TBARS level 
was observed in the SH group. Since various routes 
of administration to animals like surgical operation, 
gavage and injection are known to be stressors, this 
data could be seen as quite reasonable. Although 
TBARS assay is sensitive and widely used method to 
measure the MDA level, TBARS level does not equal 
to lipid peroxidation and it is not specific to lipid per-
oxidation. Therefore, we also measured 4-HNE level 
to confirm TBARS test results. The same trend was 
not detected in the 4-HNE levels of sham operated 
and treated rats. 
It was shown that suppression of the IL-1-mediated 
induction of COX-2/PGE2 pathway is one of the neu-
roprotective mechanism mediated by estrogen [47]. In 
addition, D-gal injection elevates COX-2 activity and 
expression in brain [48]. In parallel with these reports, 
COX-2 expression in the OD group was increased in 
comparison with C and SH groups in our study. This 
observation is also in agreement with previous find -
ings [49] indicating the importance of this enzyme in 
Figure 5. Y-maze test results in all groups. A. The time 
spent (min); B. Number of visits. The results are presented 
as mean ± SEM, n = 20 for each group. d — significant 
difference between novel arm score versus other arm score 
in all groups, p < 0.05; **Significant difference between 
novel arm score of the OD group versus the other groups,  
p < 0.05. Abbreviations as in the description of Figure 1
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the development of AD symptoms. On the other hand, 
the amount of PGE2 was found to be increased in the 
OD group compared with C and SH groups. Elevated 
level of PGE2 has been observed in the brains of AD 
patients and mice [8, 9]. In animal studies, PGE2 stim-
ulates the production of Ab by effecting b-secretase 
and b-secretase activity via some PGE2 receptors and 
promotes age-dependent oxidative damage [8, 50]. 
Consistent with previous findings, our results also 
suggested that increased levels of this molecule may 
play a critical role in the accumulation of Ab by trig-
gering inflammatory mechanisms. Additionally, our 
findings support earlier reports suggesting that inhi-
bition of COX-2 pathway and PGE2, is an important 
therapeutic target in AD. 
Anti-inflammatory effects of RA have been point-
ed in several studies [28, 51]. In a study on carcino-
genesis, RA prevented the increase in PGE2 synthesis 
and eliminated COX-2 mRNA expression [28]. Addi-
tionally, repeated administration of RA remarkably 
reduced the arthritic index and COX-2 expression in 
synovial tissue in collagen induced arthritis [51]. The 
decrease of COX-2 expression and PGE2 levels in the 
ODR group compared with the OD group indicated 
that RA might be effective in suppressing the COX-2/ 
/PGE2 pathway. Consequently, RA might be benefi-
cial in the treatment of AD by exerting anti-inflam-
matory effects and suppressing the synthesis of PGE2 
in addition to its antioxidant properties. 
One of the most important symptoms of AD is 
the impairment of cognition. As shown in previous 
studies [10, 11], increment in oxidative stress and 
estrogen deficiency, which are known to cause cogni-
tive impairment, can mimic AD-like spatial memory 
dysfunction. Therefore, we performed the Y-maze 
test as a simple spatial recognition test which has 
been widely preferred to assess hippocampus-depend-
ent short-term spatial memory [31]. We found that 
Y-maze performance was impaired in the OD group 
when the number of visits and the time spent were 
considered. Besides, the amount of time spent and 
the number of visits in the novel arm were markedly 
decreased in the OD group compared with the other 
groups. These results suggest that short-term spatial 
memory of OD rats was impaired. 
In clinical trials, it was shown that Salvia officinalis 
which contains RA, improves cognitive functions of 
patients [25, 26]. In accordance with this study, we 
found that RA significantly improved Y-maze per-
formance in the ODR group. Additionally, various 
studies have shown that Alzheimer transgenic mice 
exhibit reduced locomotor activity in an open field test 
[52, 53]. In a previous study [54], RA has been shown 
to increase the locomotor activity and motivation. 
Consistent with these studies, beside short-term spa-
tial memory, RA significantly increased the locomotor 
activity in the ODR group. It is important to note here 
that due to the increment in the locomotion, it can be 
assumed that increased novel arm frequency in the 
ODR group could be related to locomotion instead 
of improved short-term spatial memory. Although, 
the locomotion is a confounding factor for evaluation 
of Y-maze task performances, number of total arm 
entries was not different between the groups. There-
fore, these findings suggest that treatment with RA 
may be a possible therapeutic approach for alleviating 
spatial learning and memory deficits in the AD rats. 
Taken together, RA may reverse some structural 
degeneration caused by early pathological events in 
AD including lipid peroxidation and activation of 
inflammatory pathways. To our knowledge this is the 
first study evaluating the effect of RA treatment on 
lipid peroxidation, COX-2/PGE2 pathway and cog-
nitive alterations in that rat model of AD. The other 
possible mechanisms underlying this beneficial effect 
remain to be determined, but may be at least partially 
due to decrease in oxidative stress and inflammatory 
responses.
Conclusions
In conclusion, our findings support that estrogen 
deficiency with increased oxidative stress may play an 
important role in the development and progression 
of AD and this model can be used to investigate the 
mechanisms underlying AD and new therapeutic 
strategies. Furthermore, RA treatment attenuates 
memory impairments through amelioration of oxida-
tive stress and inflammatory response and is a poten-
tial candidate to slow the progression of the disease. 
Acknowledgements
This study was supported by a grant from Ak-
deniz University Research Foundation, Turkey 
(2008.02.0122.004). This study was carried out as 
part of a MSc thesis by D. Kantar Gok presented to 
Akdeniz University Health Sciences Institute.
References
1. Maccioni RB, Munoz JP, Barbeito L. The molecular bases 
of Alzheimer’s disease and other neurodegenerative disor-
ders. Arch Med Res. 2001;32:367–381. doi: 10.1016/S0188-
4409(01)00316-2.
2. Pratico D, MY Lee V, Trojanowski JQ, Rokach J, Fitzger-
ald GA. Increased F2-isoprostanes in Alzheimer’s disease: 
evidence for enhanced lipid peroxidation in vivo. FASEB J. 
1998;12:1777–1783. PMID: 9837868.
3. Schuessel K, Schafer S, Bayer TA et al. Impaired Cu/Zn-SOD 
activity contributes to increased oxidative damage in APP 
292 Deniz Kantar Gok et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2015
10.5603/FHC.a2015.0034
www.fhc.viamedica.pl
transgenic mice. Neurobiol Dis. 2005;18:89–99. doi: 10.1016/j.
nbd.2004.09.003.
4. David DC, Hauptmann S, Scherping I et al. Proteomic and 
functional analyses reveal a mitochondrial dysfunction in 
P301L tau transgenic mice. J Biol Chem. 2005;280:23802– 
–23814. doi: 10.1074/jbc.M500356200.
5. Smith CD, Carney JM, Starke-Reed PE et al. Excess 
brain protein oxidation and enzyme dysfunction in normal 
aging and in Alzheimer disease. Proc Natl Acad Sci USA. 
1991;188:10540–10543. PMID: 1683703.
6. Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other 
lipid mediators in Alzheimer’s disease. Prostaglandins Lipid 
Mediat. 2002;69:197–210. PMID: 12432919.
7. Minghetti L. Role of COX-2 in inflammatory and degener-
ative brain diseases. Subcell Biochem. 2007;42:127–141. doi: 
10.1080/07391102.2013.839960.
8. Liang X, Wang Q, Hand T et al. Deletion of the pros-
taglandin E2 EP2 receptor reduces oxidative damage 
and amyloid burden in a model of Alzheimer’s disease. 
J Neurosci. 2005;25:10180–10187. doi: 10.1523/JNEUROS-
CI.3591-05.2005.
9. Montine TJ, Sidell KR, Crews BC et al. Elevated CSF pros-
taglandin E2 levels in patients with probable AD. Neurology. 
1999;53:1495–1498. doi: 10.1212/WNL.55.2.323.
10. Hua X, Lei M, Zhang Y et al. Long-term D-galactose injection 
combined with ovariectomy serves as a new rodent model 
for Alzheimer’s disease. Life Sci. 2007;80:1897–1905. doi: 
10.1016/j.bbrc.2015.04.031.
11. Zhang X, Wang J, Xing Y et al. Effects of ginsenoside Rg1 
or 17b-estradiol on a cognitively impaired, ovariectomized rat 
model of Alzheimer’s disease. Neuroscience. 2012;220:191– 
–200. doi: 10.1016/j.neuroscience.2012.06.027.
12. Gibbs RB. Impairment of basal forebrain cholinergic neurons 
associated with aging and long-term loss of ovarian function. 
Exp Neurol. 1998;151:289–302. doi: 10.1006/exnr.1998.6789.
13. Paganini-Hill A, Henderson VW. Estrogen deficiency and 
risk of Alzheimer’s disease in women. Am J Epidemiol. 
1994;140:256–261. doi: 10.1016/0378-5122(95)93906-A.
14. Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence 
for neuronal oxidative damage in Alzheimer’s disease. Am 
J Pathol. 1996;149:21–28. PMID: 8686745.
15. Schippling S, Kontush A, Arlt S et al. Increased lipoprotein 
oxidation in Alzheimer’s disease. Free Radical Biol Med. 
2000;28:351–360. doi: 10.1016/S0891-5849(99)00247-6.
16. Green PS, Simpkins JW. Neuroprotective effects of estro-
gens: potential mechanisms of action. Int J Dev Neurosci. 
2000;18:347–358. doi: 10.1016/S0736-5748(00)00017-4.
17. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer inci-
dence and mortality in women receiving estrogen and es-
trogen-progestin replacement therapy long-term follow-up 
of a Swedish cohort. Int J Cancer. 1996;67:327–332. doi: 
10.1002/(SICI)1097-0215(19960729)67:3<327::AID-
IJC4>3.0.CO;2-T.
18. Steinberg KK, Thacker SB, Smith SJ et al. A meta-analysis 
of the effect of estrogen replacement therapy on the risk 
of breast cancer. JAMA. 1991;265:1985–1990. doi: 10.1001/
jama.1991.03460150089030.
19. Imanshahidi M, Hosseinzadeh H. The pharmacological ef-
fects of salvia species on the central nervous system. Phytother 
Res. 2006;20:427–437. doi: 10.1002/ptr.1898.
20. Mantle D, Pickering AT, Perry EK. Medicinal plant extracts 
for the treatment of dementia: a review of their pharmacology, 
efficacy and tolerability. CNS Drugs. 2000;13:201–213. 
21. Tildesley NT, Kennedy DO, Perry EK et al. Salvia lavandu-
laefolia (Spanish sage) enhances memory in healthy young 
volunteers. Pharmacol Biochem Behav. 2003;75:669–674. doi: 
10.1016/S0091-3057(03)00122-9.
22. Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, 
Scholey AB. Positive modulation of mood and cognitive 
performance following administration of acute doses of 
Salvia lavandulaefolia essential oil to healthy young volun-
teers. Physiol Behav. 2005;83:699–709. doi: 10.1016/j.phys-
beh.2004.09.010.
23. Kennedy DO, Pace S, Haskell C, Okello EJ, Milne A, Scholey AB. 
Effects of cholinesterase inhibiting sage (Salvia officinalis) on 
mood, anxiety and performance on a psychological stressor 
battery. Neuropsychopharmacology. 2006;31:845–852. doi: 
10.1038/sj.npp.1300907.
24. Scholey AB, Tildesley NT, Ballard CG et al. An extract of Salvia 
(sage) with anticholinesterase properties improves memory 
and attention in healthy older volunteers. Psychopharmacology. 
2008;198:127–139. doi: 10.1007/s00213-008-1101-3. 
25. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, 
Jamshidi AH, Khani M. Salvia officinalis extract in the 
treatment of patients with mild to moderate Alzheimer’s 
disease: A double blind, randomized and placebo-controlled 
trial. J Clin Pharm Ther. 2003;28:53–59. doi: 10.1046/j.1365-
2710.2003.00463.x.
26. Perry NSL, Bollen C, Perry EK, Ballard C. Salvia for dementia 
therapy: review of pharmacological activity and pilot tolerabil-
ity clinical trial. Pharmacol Biochem Behav. 2003;75:651–659. 
doi: 10.1016/S0091-3057(03)00108-4.
27. Petersena M, Simmonds MSJ. Rosmarinic Acid. Phytochem­
istry. 2003;62:121–125. doi: 10.1016/S0037-6337(09)70275-X.
28. Osakabe N, Yasuda A, Natsume M, Yoshikawa T. Rosma-
rinic acid inhibits epidermal inflammatory responses: anti-
carcinogenic effect of Perilla frutescens extract in the murine 
two-stage skin model. Carcinogenesis. 2004;25:549–557. doi: 
10.1093/carcin/bgh034.
29. Hohmann J, Zupkó I, Rédei D et al. Protective effects of 
the aerial parts of Salvia officinalis, Melissa Officinalis and 
Lavandula angustifolia and their constituents against en-
zyme-dependent and enzyme-independent lipid peroxidation. 
Planta Med. 1999;65:576–578. doi: 10.1055/s-2006-960830.
30. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. 
Medicinal plants and Alzheimer’s disease: from ethnobotany 
to phytotherapy. J Pharm Pharmacol. 1999;51:527–534. doi: 
10.1016/j.jep.2007.11.015.
31. Tanriover G, Sozen B, Seker A, Kilic T, Gunel M, Demir N. 
Ultrastructural analysis of vascular features in cerebral cav-
ernous malformations. Clin Neurol Neurosurg. 2013;115:438–
–444. doi: 10.1016/j.clineuro.2012.06.023.
32. Wasowicz W, Jean N, Peratz A. Optimized steps in fluoromet-
ric determination of thiobarbituric acid-reactive substances in 
serum. Importance of extraction pH and influence of sample, 
preservation and storage. Clin Chem. 1993;39:2522–2526. 
PMID: 8252725.
33. Aslan M, Yucel I, Ciftcioglu A, Savas B, Akar Y, Yucel G. 
Corneal protein nitration in experimental uveitis. Exp Biol 
Med. 2007;232:1308–1313. doi: 10.3181/0702-RM-34.
34. Dellu F, Fauchey V, Le Moal M, Simon H. Extension of a new 
two-trial memory task in the rat: influence of environmental 
context on recognition processes. Neurobiol Learn Mem. 
1997;67:112–120. doi: 10.1006/nlme.1997.3746.
35. Jamshed N, Ozair FF, Aggarwal P, Ekka M. Alzheimer 
disease in post-menopausal women: Intervene in the 
critical window period. Neurology. 2000;54:833–837. doi: 
10.4103/0976-7800.127791.
36. Rasgon NL, Magnusson C, Johansson ALV, Pedersen NL, 
Elman S, Gatz M. Endogenous and exogenous hormone expo-
293Rosmarinic acid-treated aged ovariectomized rats
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2015
10.5603/FHC.a2015.0034
www.fhc.viamedica.pl
sure and risk of cognitive impairment in Swedish twins: a pre-
liminary study. Psychoneuroendocrinology. 2005;30:558–567. 
doi: 10.1016/j.psyneuen.2005.01.004.
37. Sobow T, Kloszewska I. Modulation of age at onset in late-on-
set sporadic Alzheimer’s disease by estrogen-related factors: 
the age of menopause and number of pregnancies. German 
J Psychiatry. 2003;6:49–55.
38. Cui X, Zuo P, Zhang Q et al. Chronic systemic D-galactose 
exposure induces memory loss, neurodegeneration, and oxi-
dative damage in mice: protective effects of R-alpha-lipoic 
acid. J Neurosci Res. 2006;84:647–654. doi: 10.1002/jnr.20899.
39. Zhao HF, Li Q, Li Y. Long-term ginsenoside administration 
prevents memory loss in aged female C57BL/6J mice by mo-
dulating the redox status and up-regulating the plasticity-rela-
ted proteins in hippocampus. Neuroscience. 2011;183:189–202. 
doi: 10.1016/j.neuroscience.2011.03.048.
40. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. 
Evaluation of estrogen treatment in female patients with 
dementia of the Alzheimer type. Endocr J. 1994;41:361–371. 
doi: 10.1507/endocrj.41.361.
41. Ono K, Li L, Takamura Y et al. Phenolic compounds prevent 
amyloid b-protein oligomerization and synaptic dysfunction 
by site-specific binding. J Biol Chem. 2012;287:14631–1443. 
doi: 10.1074/jbc.M111.325456.
42. Hamaguchi T, Ono K, Murase A, Yamada M. Phenolic 
compounds prevent Alzheimer’s pathology through different 
effects on the amyloid-beta aggregation pathway. Am J Pathol. 
2009;175:2557–2565. doi: 10.2353/ajpath.2009.090417.
43. Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM. Incre-
ased lipid peroxidation precedes amyloid plaque formation 
in an animal model of Alzheimer amyloidosis. J Neurosci. 
2001;21:4183–4187. PMID: 11404403.
44. Butterfield DA, Reed T, Perluigi M et al. Elevated pro-
tein-bound levels of the lipid peroxidation product, 4-hy-
droxy-2-nonenal, in brain from persons with mild cognitive 
impairment. Neurosci Lett. 2006;397:170–173. doi: 10.1016/j.
neulet.2005.12.017.
45. Williams TI, Lynn BC, Markesbery WR, Lovell MA. 
Increased levels of 4-hydroxynonenal and acrolein, neu-
rotoxic markers of lipid peroxidation, in the brain in Mild 
Cognitive Impairment and early Alzheimer’s disease. Neu­
robiol Aging. 2006;27:1094–1099. doi: 10.1016/j.neurobiola-
ging.2005.06.004.
46. Iuvone T, Filippis D, Esposito G, D’Amico A, Izzo A. The 
spice sage and its active ingredient Rosmarinic acid protect 
PC12 cells from amyloid-b peptide-induced neurotoxicity. 
J Pharmacol Exp Ther. 2006;317:1143–1149. doi: 10.1124/
jpet.105.099317.
47. Ospina JA, Brevig HN, Krause DN, Duckles SP. Estrogen 
suppresses IL-1beta-mediated induction of COX-2 pathway in 
rat cerebral blood vessels. Am J Physiol. 2004;286:2010–2019. 
doi: 10.1152/ajpheart.00481.2003.
48. Tsai SJ, Yin MC. Anti-glycative and anti-inflammatory effects 
of protocatechuic acid in brain of mice treated by D-galac-
tose. Food Chem Toxicol. 2012;50:3198–3205. doi: 10.1016/j.
fct.2012.05.056.
49. Hoozemans JJ, O’Banion MK. The Role of COX-1 and 
COX-2 in Alzheimer’s disease pathology and the thera-
peutic potentials of non-steroidal anti-inflammatory drugs. 
Curr Drug Targets CNS Neurol Disord. 2005;4:307–315. doi: 
10.2174/1568007054038201.
50. Hoshino T, Nakaya T, Homan T et al. Involvement of pro-
staglandin E2 in production of amyloid-b peptides both in 
vitro and in vivo. J Biol Chem. 2007;282:32676–32688. doi: 
10.1016/j.jalz.2010.05.1365.
51. Youn J, Lee KH, Won J et al. Beneficial effects of rosmarinic 
acid on suppression of collagen induced arthritis. J Rheumatol. 
2003;30:1203–1207. PMID: 12784390.
52. Gortz N, Lewejohanna L, Tomma M et al. Effects of 
environmental enrichment on exploration, anxiety, and me-
mory in female TgCRND8 Alzheimer mice. Behav Brain Res. 
2008;191:43–48. doi: 10.1016/j.bbr.2008.03.006.
53. King DL, Arendash GW. Behavioral characterization of the 
Tg2576 transgenic model of Alzheimer’s disease through 
19 months. Physiol Behav. 2002;75:627–642. doi: 10.1016/
S0031-9384(02)00639-X.
54. Takeda H, Tsuji M, Inazu M, Egashira T, Matsumiya T. 
Rosmarinic acid and caffeic acid produce antidepressive-like 
effect in the forced swimming test in mice. Eur J Pharmacol. 
2002;449:261–267. doi: 10.1016/S0014-2999(02)02037-X.
Submitted: 9 July, 2015 
Accepted after reviews: 17 December, 2015 
Available as AoP: 21 December, 2015
